Featured Research

from universities, journals, and other organizations

Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy

Date:
February 5, 2005
Source:
Ludwig Institute For Cancer Research
Summary:
Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909 (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported in the Journal of Clinical Investigation. The paper shows that the CpG 7909 DNA sequence is safe, and increases the immune system's ability to recognize and destroy cancer cells.

Lausanne (February 3rd) - Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909 (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported today in the Journal of Clinical Investigation. The paper shows that the CpG 7909 DNA sequence is safe, and increases the immune system's ability to recognize and destroy cancer cells. The Phase I study was conducted by the Lausanne Branch of the Ludwig Institute for Cancer Research (LICR) at the Lausanne University Hospital in Switzerland, in the framework of the international Cancer Vaccine Collaborative (CVC), a partnership established by the New York-based Cancer Research Institute (CRI) and the LICR.

"What we're doing is testing a novel adjuvant, a compound that stimulates the immunological response to a vaccine, which is essentially tricking the immune system into thinking the vaccine is a bacterial infection," says lead author Dr. Daniel Speiser from the LICR Lausanne Branch. "The immune system mounts a response against the peptide antigen, the cancer-specific target, in the vaccine, and thus also against the antigen on the cancer cells."

The vaccine, combining the CpG 7909 adjuvant and Incomplete Freund's Adjuvant (IFA) with a synthetic peptide (protein fragment) from a melanoma antigen known as Melan-A/MART-1, induced CD8+ T cells that specifically recognized cells displaying Melan-A/MART-1 on their surface. This T cell response occurred in all eight patients in the trial. Responses were one order of magnitude higher than those observed in eight patients who received the Melan-A/MART-1 antigen with IFA but without CpG 7909 in previous studies.

According to Dr. Jill O'Donnell-Tormey, the Executive Director of CRI, the trial is part of the CVC's systematic, coordinated vaccine development approach that compares single vaccine variables in parallel. "We've identified many cancer antigens, and the challenge is to determine which cancer vaccine compositions induce a strong and sustained immune response against particular antigens. The results from this trial represent a substantial step forward in this regard. This conclusion is justified because we are using reproducible immunological monitoring across the CVC, allowing a more accurate comparison of the effects of CpG 7909 in this trial with the results of several other adjuvants that have been tested in other trials. By comparing single variables in parallel we believe we can develop effective cancer vaccines in a much shorter time than the conventional approach of trying variables sequentially." The CVC has clinical research sites in Australia, Belgium, Germany, Japan, Switzerland, the UK and the USA.


Story Source:

The above story is based on materials provided by Ludwig Institute For Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

Ludwig Institute For Cancer Research. "Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy." ScienceDaily. ScienceDaily, 5 February 2005. <www.sciencedaily.com/releases/2005/02/050204214729.htm>.
Ludwig Institute For Cancer Research. (2005, February 5). Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2005/02/050204214729.htm
Ludwig Institute For Cancer Research. "Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy." ScienceDaily. www.sciencedaily.com/releases/2005/02/050204214729.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins